2-methyl-cyclohexanol | 808751-97-5

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 2-methyl-cyclohexanol
• 英文别名: (2R)-2-methylcyclohexan-1-ol
• CAS: 808751-97-5
• 化学式: C₇H₁₄O
• mdl: MFCD30172197
• 分子量: 114.188
• InChiKey: NDVWOBYBJYUSMF-ULUSZKPHSA-N

物化性质

• 沸点：
  170.3±8.0 °C(Predicted)
• 密度：
  0.925±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  8
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  20.2
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  2-methyl-cyclohexanol 在 (5,10,15,20-tetrakis(pentafluorophenyl)porphyrinato)iron(III) chloride 间氯过氧苯甲酸 作用下， 以 二氯甲烷 、 乙腈 为溶剂， 反应 0.17h， 以62.6%的产率得到(R)-2-methylcyclohexanone
  参考文献：
  名称：

  铁（III）卟啉配合物的仿生醇氧化：与细胞色素P-450催化氧化的相关性和参与的两个状态的自由基反弹机制

  摘要：

  广泛的系统氧化反应 酒类 通过使用铁卟啉配合物进行了研究，以了解它们与铁卟啉的关系。 细胞色素P-450酶并在有机合成中有实际应用。卟啉铁配合物有效催化酒精氧化 到各自 羰基化合物 通过高价的铁-氧卟啉中间体（（Porp）Fe O +）。几种机理研究，例如同位素18 O贴标，氘同位素效应，线性自由能关系和自由基钟底物的开环表明， 酒精被一系列涉及α-羟烷基自由基中间体和氧回弹的反应氧化而形成宝石-二醇，脱水会产生 羰基化合物。此外，已经提出，如P-450酶所显示的，铁卟啉模型系统中的醇氧化反应也可以采用二态反应机理。

  DOI：

  10.1039/b414603d

文献信息

• DENDRITIC NANO-ANTIOXIDANTS
  申请人：Lee Choon Young

  公开号：US20100247439A1

  公开（公告）日：2010-09-30

  Provided are dendritic nano-antioxidant compounds according to Formula I, which may further comprise active agents covalently or non-covalently attached. Further provided are compositions comprising the disclosed compounds. Also disclosed are cosmetic compositions and dietary supplements comprising the compounds according to Formula I. The invention additionally provides methods of reducing free radicals or oxidative stress in a cell, a method of treating a subject, and a method of treating a condition comprising administering the compounds according to Formula I.

  本发明提供了公式I的树突型纳米抗氧化化合物，该化合物可以进一步包含共价或非共价附着的活性剂。还提供了包含所述化合物的组合物。还公开了包含公式I的化合物的化妆品组合物和膳食补充剂。此外，本发明还提供了减少细胞中自由基或氧化应激的方法，治疗受试者的方法以及治疗包括给予公式I的化合物的病症的方法。
• PYRAZOLO [4,3-c] CINNOLIN-3-ONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS
  申请人：Beshore Douglas C.

  公开号：US20110301167A1

  公开（公告）日：2011-12-08

  The present invention is directed to pyrazolo[4,3-c]cinnolin-3-one compounds of formula (I) which are M1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the M1 receptor is involved, such as Alzheimer's disease, schizophrenia, pain or sleep disorders. The invention is also directed to pharmaceutical compositions comprising the compounds, and to the use of the compounds and compositions in the treatment of diseases mediated by the M1 receptor.

  本发明涉及式(I)的吡唑并[4,3-c]茚啉-3-酮化合物，它们是M1受体正向变构调节剂，可用于治疗M1受体介导的疾病，如阿尔茨海默病、精神分裂症、疼痛或睡眠障碍。本发明还涉及包含这些化合物的药物组合物，以及使用这些化合物和组合物治疗M1受体介导的疾病的方法。
• Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors
  申请人：Incyte Holdings Corporation

  公开号：EP2343299B9

  公开（公告）日：2017-03-08
• NOVEL CHIRAL CYCLOHEXYL COMPOUNDS
  申请人：THE SECRETARY OF STATE FOR DEFENCE

  公开号：EP0767772B1

  公开（公告）日：2000-08-30
• Method for Purifying Polymerizable Fluoromonomer by Distillation
  申请人：Central Glass Company, Limited

  公开号：US20210317065A1

  公开（公告）日：2021-10-14

  The present invention is directed to a purification method for purifying a fluorine-containing polymerizable monomer of the formula (1), in which the fluorine-containing polymerizable monomer is purified by distillation in the coexistence of a phenolic compound A such as 6-tert-butyl-2,4-xylenol and a phenolic compound B such as 2,2′-methylene-bis(4-methyl-6-tert-butylphenol). By the combined use of the phenolic compound A and the phenolic compound B, it is possible to significantly suppress polymerization or oligomerization of the fluorine-containing polymerizable monomer even during industrial-production-scale distillation and efficiently purify the fluorine-containing polymerizable monomer by distillation.